Read by QxMD icon Read


Pim B Olthof, Fadi Rassam, Thomas M van Gulik
INTRODUCTION: ALPPS (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy) is a new two-stage hepatectomy for patients in whom conventional treatment is not feasible due to insufficient future liver remnant (FLR). During stage one of ALPPS, accelerated growth of the FLR is induced by ligation of the portal vein and in situ split of the liver, which prevents interlobar collateral portal circulation and attributes to the accelerated hypertrophy response. This can present a risk for postoperative haemorrhage...
April 6, 2018: International Journal of Surgery Case Reports
Kevin M Lewis, Shelly Ikeme, Tolu Olubunmi, Carl Erik Kuntze
Intraoperative surgical sealants and hemostatic agents have been shown to reduce postoperative complications, transfusions and hospital resource utilization. Despite availability of these agents, the incidence and burden of bleeding remains high and surgeons' requirements for hemostatic control continue to evolve. A burgeoning class of hemostatic agents are hemostatic patches, which offer package-to-patient readiness and direct application. In addition, hemostatic patches may provide tissue sealing capabilities...
April 16, 2018: Expert Review of Medical Devices
Tristan van Doormaal, Ahmet Kinaci, Sander van Thoor, Saskia Redegeld, Wilhelmina Bergmann, Albert van der Zwan
BACKGROUND: Cerebrospinal fluid (CSF) leakage occurs in 4% to 32% of cranial surgeries and is associated with significant patient burden and expense. The use of sealant as an adjunct to primary dural closure is assumed to help prevent CSF leakage. OBJECTIVE: To examine the utility of different sealants for dural closure using an in Vitro model. METHODS: We evaluated 9 commonly used dural sealants, including Tachosil (Takeda Inc, Osaka, Japan), Adherus (Hyperbranch Inc, Durham, North Carolina), Duraform (Codman, Raynham, Massachusetts), Tissudura (Baxter, Deerfield, Illinois), Hemopatch (Baxter), TissuePatchDural (Tissuemed, Leeds, United Kingdom), Tisseel (Baxter), Duragen Secure (Integra, Plainsboro, New Jersey), and Duraseal, (Integra)...
December 21, 2017: Operative Neurosurgery (Hagerstown, Md.)
Shelly Ikeme, Luca Weltert, Kevin M Lewis, Gerhard Bothma, Daniela Cianciulli, Nicole Pay, Josh Epstein, Erik Kuntze
BACKGROUND: A recent randomized controlled trial showed that patients undergoing ascending aorta surgery treated with HEMOPATCH to control bleeding had a significantly better hemostasis success rate than with dry or wet gauze compression or similar standard of care (SOC). OBJECTIVE: To compare the cost-effectiveness using two different agents for hemostasis (HEMOPATCH vs dry or wet gauze compression or similar SOC) in cardiac surgery from the European hospital perspective...
March 2018: Journal of Medical Economics
Marcel A Boerman, Edwin Roozen, María José Sánchez-Fernández, Abraham R Keereweer, Rosa P Félix Lanao, Johan C M E Bender, Richard Hoogenboom, Sander C Leeuwenburgh, John A Jansen, Harry Van Goor, Jan C M Van Hest
In order to prevent hemorrhage during surgical procedures, a wide range of hemostatic agents have been developed. However, their efficacy is variable; hemostatic devices that use bioactive components to accelerate coagulation are dependent on natural sources, which limits reproducibility. Hybrid devices in which chain-end reactive poly(ethylene glycol) is employed as active component sometimes suffer from irregular cross-linking and dissolution of the polar PEG when blood flow is substantial. Herein, we describe a synthetic, nonbioactive hemostatic product by coating N-hydroxysuccinimide ester (NHS)-functional poly(2-oxazoline)s (POx-NHS) onto gelatin patches, which acts by formation of covalent cross-links between polymer, host blood proteins, gelatin and tissue to seal the wound site and prevent hemorrhage during surgery...
August 14, 2017: Biomacromolecules
Luca Weltert, Salvatore D'Aleo, Ilaria Chirichilli, Mauro Falco, Franco Turani, Alessandro Bellisario, Ruggero De Paulis
OBJECTIVE: Hemostasis is a critical component of all surgical procedures and especially cardiac surgery. In addition to traditional means, topical hemostatic agents have been reported to be extremely effective in terminating bleeding during cardiac procedures. We compared a hemostatic matrix sealant agent (HEMOPATCH Baxter Healthcare Corporation, Deerfield, IL) with alternative topical hemostatic treatment in patients undergoing ascending aorta surgery with moderate bleeding. MATERIALS AND METHODS: Following sample size calculation, in a prospective randomized study design, 85 patients were treated with HEMOPATCH matrix sealant and 85 patients received alternative treatment (dry or wet gauze compression or similar [control group])...
July 29, 2016: Surgical Technology International
Frank Ulrich, Giuseppe Maria Ettorre, Luca Weltert, Martin Oberhoffer, Huub Kreuwel, Rafaella De Santis, Erik Kuntze
INTRODUCTION: Haemostasis is a critical part of surgery. Haemostatic agent selection is based upon a number of factors including surgeon's experience and choice. This post-marketing survey determined surgeons' intraoperative use and perception of Hemopatch® (Baxter Healthcare Corporation, Deerfield, IL), a resorbable collagen-based sealing haemostat. METHODS AND PARTICIPANTS: A one-arm questionnaire was distributed to European general, cardiac, pulmonary, and urologic surgeons who used Hemopatch® to achieve haemostasis in situations where bleeding control by pressure, ligature, or conventional procedures had been ineffective or was impractical...
April 2016: Surgical Technology International
Bernhard Baumgartner, Wolfgang Draxler, Kevin M Lewis
PURPOSE: The perioperative management of patients on antithrombotic therapy is currently an unresolved problem as these therapies pose a considerable risk for perioperative hemorrhagic complications. The presented studies investigated the efficacy of a new collagen technology to achieve hemostasis. A polyethylene glycol-coated collagen pad (PCC) was compared to a marketed fibrinogen-thrombin coated collagen pad (FTC) for the treatment of an aortotomy incision in heparinized swine on dual antiplatelet therapy...
December 2016: Journal of Investigative Surgery: the Official Journal of the Academy of Surgical Research
Stany Sandrio, Ariawan Purbojo, Robert A Cesnjevar, André Rüffer
As survival among patients with complex congenital heart disease continues to improve, long-term survivors frequently require redo surgical procedures, with potentially escalating technical difficulty and bleeding risk. This report describes our experience with a new hemostatic pad, Hemopatch (Baxter Deutschland GmbH, Unterschleissheim, Germany) in redo cardiac surgery.
February 2016: Annals of Thoracic Surgery
Kevin Michael Lewis, Carl Erik Kuntze, Heinz Gulle
The need for advanced hemostatic agents increases with the complexity of surgical procedures and use of anticoagulation and antiplatelet treatments. HEMOPATCH (Sealing Hemostat) is a novel, advanced hemostatic pad that is composed of a synthetic, protein-reactive monomer and a collagen backing. The active side is covered with a protein-reactive monomer: N-hydroxysuccinimide functionalized polyethylene glycol (NHS-PEG). NHS-PEG rapidly affixes the collagen pad to tissue to promote and maintain hemostasis. The combined action of the NHS-PEG and collagen is demonstrated to have benefit relative to other hemostatic agents in surgery and preclinical surgical models...
2016: Medical Devices: Evidence and Research
Roberto Ruggiero, Ludovico Docimo, Salvatore Tolone, Maurizio De Palma, Mario Musella, Angela Pezzolla, Adelmo Gubitosi, Domenico Parmeggiani, Raffaele Pirozzi, Simona Gili, Simona Parisi, Antonio D'Alessandro, Giovanni Docimo
INTRODUCTION: Hemostasis during thyroidectomy is essential; however the most efficient and cost-effective way to achieve this is unclear. The aim of this study was to evaluate the outcome of total thyroidectomy (TT) performed with the combination of harmonic scalpel (HS) and an advanced hemostatic pad (Hemopatch). METHODS: Patient undergone TT were divided into two groups: HS + hemopatch and HS + traditional hemostasis groups. The primary endpoint was 24-h drain output and blood-loss requiring reintervention...
April 2016: International Journal of Surgery
Jayant S Jainandunsing, Sali Al-Ansari, Bozena D Woltersom, Thomas W L Scheeren, Ehsan Natour
Treatment of damaged cardiac tissue in patients with high bleeding tendency can be very challenging, damaged myocardial tissue has a high rupture risk when being sutured subsequently on-going bleeding is a major risk factor for poor clinical outcome. We present a case demonstrating the feasibility in using a novel haemostatic collagen sponge for the management of a myocardial wound. This report is the first description in cardiac surgery where Hemopatch sponges are used to successfully seal a left ventricle wound...
2015: Journal of Cardiothoracic Surgery
Abe Fingerhut, Selman Uranues, Giuseppe Maria Ettorre, Emanuele Felli, Marco Colasanti, Gregorio Scerrino, Giusepina Irene Melfa, Cristina Raspanti, Gaspare Gulotta, Alexander Meyer, Martin Oberhoffer, Michael Schmoeckel, Luca Paolo Weltert, Graziano Vignolini, Matteo Salvi, Lorenzo Masieri, Guido Vittori, Giampaolo Siena, Andrea Minervini, Sergio Serni, Marco Carini
Topical hemostatic agents that can seal tissues and assist in the coagulation cascade of patients undergoing surgery have been readily available for several decades. Using either synthetic or animal/plant-derived materials, these agents represent a powerful tool to reduce postoperative bleeding complications in cases where mechanical or energy-driven hemostasis is not possible or insufficient. Recently, a novel sealing hemostatic patch, HEMOPATCH (Baxter International, Deerfield, IL), was developed. The device is a thin and flexible patch consisting of a specifically-formulated porous collagen matrix, coated on one side with a thin protein-binding layer...
November 2014: Surgical Technology International
F Imkamp, Y Tolkach, M Wolters, S Jutzi, M Kramer, T Herrmann
PURPOSE: Nephron-sparing surgery (NSS) is the gold standard treatment for resectable renal tumors. In the last decade, laparoscopic partial nephrectomy (LPN) has evolved in technical, surgical and oncological aspects and is an accepted treatment option for local-stage renal tumors. Improvements in not only surgical techniques, but also potent hemostats have encouraged this evolution. Here, we report our initial experiences with a new hemostatic agent, Hemopatch(®) (polyethylene glycol-coated collagen patch, Baxter), in zero-ischemia LPN...
October 2015: World Journal of Urology
Kevin M Lewis, Alexandra Schiviz, Hans-Christian Hedrich, Johannes Regenbogen, Andreas Goppelt
PURPOSE: Currently available hemostatic pads are effective in treating oozing bleeds, but otherwise ineffective in more severe bleeding. This study investigates the hemostatic efficacy of a new hemostatic pad with advanced sealing properties using protein-reactive polyethylene glycol-coated collagen (PCC, Hemopatch) versus an oxidized regenerated cellulose (ORC, Tabotamp/Surgicel Original) in a leporine arterial bleeding model of vascular reconstruction and a porcine hepatic model of general surgery...
2014: International Journal of Surgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"